Open AccessLobular breast cancer metastasis to uterus during adjuvant tamoxifen treatment
Author(s) -
Aydın Aytekin,
İrem Bilgetekin,
Aydın Çiltaş,
Betül Öğüt,
Uğur Coşkun,
Mustafa Benekli
Publication year - 2018
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.187235
Subject(s) - tamoxifen , medicine , breast cancer , endometrial cancer , uterus , oncology , hormonal therapy , metastasis , lobular carcinoma , context (archaeology) , cancer , ductal carcinoma , biology , paleontology
Tamoxifen plays a critical role in the treatment of hormone receptor-positive breast cancer. Despite these great benefits against breast cancer, tamoxifen increases the risk of endometrial pathologies such as endometrial hyperplasia, polyp, and neoplasms because of agonistic effect on endometrial tissues. Therefore, gynecologic follow-up should be carried out during tamoxifen treatment. Uterine tumors are frequently detected as the result of presentation with abnormal uterine bleeding. In addition, genital tract's metastases from distant primary tumors can present with abnormal uterine bleeding. Therefore, it is important to determine whether the uterine mass is metastatic or primary because different treatment modalities are used for them. In this context, breast carcinomas are the most frequent metastatic tumors, particularly invasive lobular carcinoma. Here, we report an invasive lobular carcinoma case that presented with abnormal uterine bleeding while receiving tamoxifen therapy and has metastasize in the uterus.